This week the biggest story in clinical trial results came out of an obesity trial: Eli Lilly's retatrutide — a once-weekly shot that activates three different appetite-and-metabolism hormones (GIP, GLP-1, and glucagon) at the same time — helped adults with obesity lose an average of roughly 30% of their body weight at 80 weeks. That level of weight loss was previously only seen with bariatric surgery. We also unpack a TROP-2 antibody-drug conjugate from Merck and Kelun-Biotech thatscored back-to-back Phase 3 wins in two tough cancers, plus a novel approach to gout and a new mechanism for stubborn high blood pressure.
In Part 1 we cover:1. Eli Lilly — Retatrutide for Obesity (Phase 3)2. Merck — Sacituzumab Tirumotecan (sac-TMT) for Advanced or Recurrent Endometrial Cancer (Phase 3)3. Kelun-Biotech — Sacituzumab Tirumotecan (sac-TMT) for First-Line Advanced Triple-Negative Breast Cancer (Phase 3)
4. Sobi — Pozdeutinurad for Gout (Phase 3)5. Mineralys Therapeutics — Lorundrostat for Uncontrolled and Resistant Hypertension, Including Patients With Chronic Kidney Disease (Phase 3)
The retatrutide readout matters because obesity affects more than a billion people globally, and an injectable medicine reaching surgery-level weight loss could change how doctors and patients think about treatment — moving it from a'maybe later' option to a frontline tool. The same week's sac-TMT cancer wins point to a new class of 'guided-missile' chemotherapy that homes in on the TROP-2 protein found on many tumors, and the gout and hypertension readoutsboth crack open therapy classes that have been stuck for decades.
Part 2 drops Thursday. Subscribe at TrialBreaks.com#biomedicine #clinicaltrials #science #obesity #GLP1 #oncology #breastcancer #endometrialcancer #ADC #cardiology #hypertension #gout #immunotherapy #drugdiscovery